AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Koa Wealth Management LLC

Koa Wealth Management LLC grew its position in AstraZeneca PLC (NASDAQ:AZN) by 35.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 25,678 shares of the company’s stock after acquiring an additional 6,698 shares during the quarter. AstraZeneca comprises approximately 1.5% of Koa Wealth Management LLC’s portfolio, making the stock its 21st biggest position. Koa Wealth Management LLC’s holdings in AstraZeneca were worth $2,001,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. CIBC Asset Management Inc increased its position in AstraZeneca by 2.3% in the 3rd quarter. CIBC Asset Management Inc now owns 238,268 shares of the company’s stock valued at $18,563,000 after acquiring an additional 5,269 shares during the period. OneDigital Investment Advisors LLC grew its stake in shares of AstraZeneca by 5.1% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 27,645 shares of the company’s stock valued at $2,154,000 after purchasing an additional 1,333 shares during the last quarter. Zions Bancorporation N.A. increased its holdings in shares of AstraZeneca by 36.1% in the third quarter. Zions Bancorporation N.A. now owns 12,332 shares of the company’s stock valued at $961,000 after purchasing an additional 3,272 shares during the period. Huntington National Bank raised its stake in shares of AstraZeneca by 7.9% during the third quarter. Huntington National Bank now owns 13,899 shares of the company’s stock worth $1,083,000 after purchasing an additional 1,022 shares during the last quarter. Finally, ICICI Prudential Asset Management Co Ltd lifted its holdings in shares of AstraZeneca by 18.8% during the third quarter. ICICI Prudential Asset Management Co Ltd now owns 7,601 shares of the company’s stock worth $592,000 after purchasing an additional 1,205 shares during the period. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

NASDAQ AZN opened at $63.23 on Friday. The business has a 50 day moving average price of $75.03 and a 200 day moving average price of $78.20. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.69. The company has a market capitalization of $196.05 billion, a P/E ratio of 30.25, a PEG ratio of 1.20 and a beta of 0.47. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The business had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.87 earnings per share. Sell-side analysts expect that AstraZeneca PLC will post 4.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on AZN. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. TD Cowen lifted their price objective on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Finally, Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.